Background. Thrombotic thrombocytopaenic purpurahaemolytic uraemic syndrome (TTP-HUS) in SLE was reported mainly in isolated case reports. The aim of this study is to investigate the clinical and pathological features, outcome and possible pathogenesis of TTP-HUS in patients with lupus nephritis. Methods. Clinical and renal histopathological data of patients with lupus nephritis were reviewed for clinical and pathological evidence of both TTP-HUS and renal thrombotic microangiopathy (TMA). Serum ADAMTS-13 activity and ADAMTS-13 autoantibodies were further studied. Results. Seven patients with evidence of both TTP-HUS and renal TMA were identified in 353 patients with lupus nephritis. In comparison with 55 patients with lupus nephritis without TTP-HUS, those with TTP-HUS had a higher prevalence of acute renal failure and worse renal outcome. The serum ADAMTS-13 activity was significantly lower in patients with both lupus nephritis and TTP-HUS than in patients with lupus nephritis only and in normal control (40% versus 69%, P = 0.012; 40% versus 81%, P < 0.001, respectively). The prevalence of ADAMTS-13 autoantibodies was significantly higher in patients with both lupus nephritis and TTP-HUS than in patients with lupus nephritis only and in normal control (6/7, 86% versus 10/55, 18%, P < 0.001; 6/7, 86% versus 0, P < 0.001, respectively). After clinical remission, the serum ADAMTS-13 activity of the seven patients with TTP-HUS increased significantly (40% versus 63%, P < 0.001) and five out of the six patients with positive ADAMTS-13 autoantibodies turned negative. Conclusions. ADAMTS-13 autoantibodies might play an important role in the pathogenesis of TTP-HUS associated with lupus nephritis. The long-term outcome seems to be worse in patients with both TTP-HUS and lupus nephritis than in patients with lupus nephritis alone.
Introduction
Thrombotic thrombocytopaenic purpura-haemolytic uraemic syndrome (TTP-HUS) is a clinical life-threatening syndrome characterized by microangiopathic haemolytic anaemia (MAHA), thrombocytopaenia, fever, acute renal impairment and/or neurologic impairment [1] . About 90% of the TTP-HUS is idiopathic and the remainder occurs in association with infection, malignancy, medications, pregnancy, malignant hypertension and rheumatic diseases such as systemic lupus erythematosus (SLE). In the literature, TTP-HUS in SLE was reported mainly in isolated case report. The prevalence and characteristics, especially long-term outcome, and pathogenesis of patients with TTP-HUS in lupus nephritis are unclear.
Von Willebrand factor (vWF) is the largest adhesive multimeric blood glycoprotein, which is the carrier protein for the plasma coagulation protein factor VIII (F-VIII) and promotes platelet adhesion and subsequent aggregation at the sites of vascular damage. A disintegrin and metalloprotease with thromobospondin type I repeats 13 (ADAMTS-13) is discovered to be the vWF-cleaving protease (vWF-cp) [2] [3] [4] . Recent studies showed that the deficiency or dysfunction of ADAMTS-13 could result in the survival of uncleaved or partially cleaved unusually large vWF multimers (UL-vWF) and these were regarded as the major cause of idiopathic TTP [1, 5, 6] . It was also suggested that autoantibodies against ADAMTS-13 might take part in the pathogenesis of TTP in patients with autoimmune diseases [1, 6] .
The purpose of this study was to investigate the prevalence, clinicopathological features, outcome and possible pathogenesis of patients with TTP-HUS in a large cohort of Chinese patients with lupus nephritis.
Materials and methods

Patients
Clinical and renal histopathological data of patients with renal biopsyproven lupus nephritis, diagnosed between January 2000 and December 146 F. Yu et al. 2007 in Peking University First Hospital, were reviewed for clinical and pathological evidence of both TTP-HUS and renal thrombotic microangiopathy (TMA). TTP-HUS was characterized by MAHA and thrombocytopaenia, fever, acute renal impairment and/or neurologic impairment. Renal TMA was characterized by interlobular artery, arteriole and glomerular capillary lesions, including endothelial cell swelling, lumen narrowing or obliteration and thrombi formation by light microscopy (LM). Swelling of glomerular endothelial cells, detachment from the glomerular basement membrane and widening of the subendothelial space were identified by electron microscopy (EM). Known causes of renal TMA, including antiphospholipid syndrome (APS), scleroderma, disseminated intravascular coagulation (DIC), pregnancy-associated TMA, malignant hypertension and drug-associated TMA, were further excluded. Then the detailed clinical and pathological data of selected patients with lupus nephritis and TTP-HUS were retrospectively analysed.
The patients fulfilled the 1997 American College of Rheumatology revised criteria for SLE [7] . The disease activity was assessed by the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) [8, 9] . Pathological types of lupus nephritis were classified according to the International Society of Nephrology/Renal Pathology Society 2003 revised classification [10] .
The remission of lupus nephritis includes complete remission and partial remission detailed in previous works [11] [12] [13] [14] . The remission of TTP-HUS was defined as the disappearance of clinical features with remission of haemolytic anaemia, normalization of peripheral platelet count and serum lactic acid dehydrogenase (LDH).
The patients were followed up after clinical remission. The primary end point was defined as end-stage renal disease (ESRD) and secondary end point was defined as doubling of serum creatinine.
Informed consent was obtained from each patient for blood sampling and renal biopsy. The research was in compliance with the Declaration of Helsinki.
Renal pathology
The renal biopsy specimens were examined by direct immunofluorescence (IF), LM and EM techniques. The renal biopsy specimens were fixed in 4.5% buffered formaldehyde for LM and fixed in 2.5% paraformaldehyde for EM. Consecutive serial 3 µm sections were used for histological staining. Stains employed included haematoxylin and eosin (H&E), periodic acid-Schiff (PAS), silver methenamine (Meth) and Masson's trichrome. EM was performed according to standard procedures. After being embedded in epon, ultrathin sections were mounted on metal grids and stained with uranyl acetate before being viewed under a transmission electron microscope (JEM-1230; JEOL, Tokyo, Japan). Pathological parameters such as activity indices (AI), including endocapillary hypercellularity, cellular crescents, karyorrhexis/fibrinoid necrosis, subendothelial hyaline deposits, interstitial inflammation and leucocyte infiltration, and chronicity indices (CI), including glomerular sclerosis, fibrous crescents, tubular atrophy and interstitial fibrosis, were approached by renal pathologists using a modification of a previously reported system [15] involving semiquantitative scoring of specific biopsy features.
Blood samples
For detection of ADAMTS-13 activity and ADAMTS-13 autoantibodies, sera were obtained from peripheral blood on the same day of the renal biopsy before initiation of immunosuppressive treatment. Sera from 50 healthy individuals with matched gender and age were collected and used as normal controls. All sera were stored at −20 • C until use.
ADAMTS-13 activity assay
The ADAMTS-13 activity was assessed using a residual collagen-binding assay (R-CBA) with some minor modification [16] . In brief, microtitre plates (Costar, USA) were coated with 100 µL/well of collagen type III at 5 µg/mL in 0.025 mol/L Tris-buffered saline (TBS), incubated at 4 • C overnight and then blocked with 2.5% BSA. In each step, the plates were washed with TBS containing 0.1% Tween-20 (TBST); 100 µL of sera from patients or normal controls were dialysed at room temperature for 3 h in dialysis buffer (0.005 mol/L Tris-base, 0.1% Tween-20, 1.5 mol/L urea, pH 8.3) in order to activate ADAMTS-13 [2] . As a control, 15 µL of the same sample was kept at room temperature during dialysis. Then the dialysed sera were diluted 1:20 in TBST with 10 mmol/L BaCl 2 (Ba 2+ can also activate ADAMTS-13), and the control samples in TBST. The diluted samples (100 µL) were added in duplicate to the wells of the plates and incubated at 37 • C for 1 h. The HRP-labelled rabbit anti-human vWF polyclonal antibody (1:8000) was added and incubated at 37 • C for 0.5 h. After incubation, the plates were washed and developed with OPD. The plates were read on a microplate reader (Model 680, BioRad, USA) at 490 nm. Data were analysed as the percentage of collagen-binding activity remaining after dialysis compared to the collagen binding activity in the individual's baseline sample. One hundred percent minus the residual collagen-binding activity was arbitrarily regarded as the ADAMTS-13 activity.
Inter-assay precision was determined by evaluating single normal human plasma in 10 consecutive assay runs for ADAMTS-13 activity determination. The results were expressed as the inter-assay percent CV (coefficient of variation) according to the standard formula: %CV = SD/ mean × 100. The inter-assay percent CV was found to be <10% and therefore in the range considered to be acceptable for immunoassays [17] .
Detection of the ADAMTS-13 autoantibody by Western blot analysis
Recombinant ADAMTS-13 (15.75 µg) (kindly donated by Dr Scheiflinger, Baxter BioScience, Biomedical Research Center) was prepared in non-reducing condition. After boiling for 5 min and ultracentrifugation, the sample was loaded onto an 8% polyacrylamide gel, and electrophoresed at 120 V for 3 h. Proteins were transferred to a nitrocellulose (NC) membrane at 32 mA for 2.5 h. The NC membrane was blocked in 3% skimmed milk in 0.01 mol/L Tris/HCl buffer with 0.1% Tween-20 (TBST) for 1 h at 37 • C and then was cut into strips, which were incubated with test sera diluted in 1:50 overnight at 4 • C. The membrane was washed with TBST three times and then incubated with the appropriate alkaline phosphatase-conjugated goat anti-human IgG antibody (Sigma, USA) diluted in 1:6000 for 1 h at room temperature. A colour was developed by the addition of an appropriate substrate: nitroblue-tetrazoleum (NBT) and 5-bromo-4-chloro-3-indolyl phosphate (BCIP). The reaction was stopped with distilled water.
Statistical analysis
For statistical analysis, the statistical software SPSS 12.0 (SPSS, Chicago, IL, USA) was employed. Quantitative data were expressed as median with range (minimum, maximum). For comparison of clinical and pathological features of patients, Student's t-test, one-way ANOVA analysis of variance and chi-square test were used. Statistical significance was considered as P < 0.05.
Results
Demographic features of patients with lupus nephritis and TTP-HUS
Seven out of the 353 patients with lupus nephritis who underwent consecutive renal biopsies were diagnosed with both TTP-HUS and renal TMA. Six of the seven were females and one was male with a median age of 27 (18 to 53) years. SLE and TTP-HUS were diagnosed concomitantly in five patients, one patient was diagnosed with SLE before the onset of TTP-HUS (interval: 16 years) and the other one was diagnosed with TTP-HUS before SLE (interval: 5 years) ( Table 1) .
Clinical and laboratory features
The detailed clinical and laboratory features of the seven patients are listed in Tables 1 and 2 .
All patients presented with hypertension. Six patients presented with non-infectious fever and three presented with a neurological disorder such as headache, seizure or confusion. All patients had evidence of MAHA such as anaemia (seven patients), increased reticulocyte count 
0 (seven patients), elevated LDH (seven patients), negative Coombs' test (six patients) and increased peripheral schistocyte count (six patients). Thrombocytopaenia was found in all patients and the median platelet count was 66 × 10 9 /L (range 31-89 × 10 9 /L, normal range 100-300 × 10 9 /L). The median proteinuria was 4.32 g/24 h (range 1.09-6.78 g/24 h, normal range <150 mg/day). The median value of serum creatinine was 4.2 mg/dL (range 1.3-11.2 mg/dL, normal range 0.5-1.5 mg/dL) upon diagnosis. All patients had hypocomplementaemia, and the median value of serum C3 was 0.42 g/L (range 0.21-0.76 g/L, normal range >0.8 g/L). The median SLEDAI was 20 (range 15-36).
Renal pathological features
As shown in Table 3 , all seven patients had diffuse proliferative lupus nephritis (IV-G), including two with IV-G(A) and five with IV-G(A/C) (according to the 2003 revised ISN/RPS classification [10] ). The median AI and CI was 12 (range 7-15) and 5 (range 2-9), respectively.
The renal pathological features including TMA features of the seven patients are listed in Table 3 . The light micrograph is shown in Figure 1 . 
Treatment and outcome
As shown in Table 4 , five patients received plasmapheresis and two received plasma infusion. All patients received methylprednisone pulse therapy and subsequent oral Type 
Serum ADAMTS-13 activity and serum autoantibodies against ADAMTS-13 in patients with lupus nephritis and TTP-HUS
The median serum ADAMTS-13 activity in patients with lupus nephritis and TTP-HUS was 40% (ranging from 34% to 55%). In comparison with 50 normal individuals (81%, ranging from 57% to 109%), the activity in patients was significantly lower (P < 0.001) (Figure 2a ).
The IgG ADAMTS-13 autoantibodies were detected in six out of the seven patients (86%) by Western blot analysis. The 175-kD protein could be blotted [18] (Table 2) . None of the 50 healthy controls were positive for ADAMTS-13 autoantibodies.
After clinical remission, all of the seven patients were reexamined for the ADAMTS-13 activity and ADAMTS-13 autoantibodies. All of the activity increased (40% versus 63%, P < 0.001, Figure 2b ) and five out of the six patients with positive antibodies in the active phase turned negative after clinical remission (detail in Table 2 ).
Comparison between patients with diffuse proliferative lupus nephritis with and without TTP-HUS
In order to improve the quality of our analysis, the patients with diffuse proliferative lupus nephritis (IV-G) Fig. 2. (a) The ADAMTS-13 activity in patients with lupus nephritis plus TTP-HUS (LN+HUS-TTP), lupus nephritis only (LN only) and normal controls. The horizontal solid lines indicate the mean values for each group. The levels of ADAMTS-13 activity were expressed in percentage. The level was significantly lower in patients with lupus nephritis plus TTP-HUS than in patients with lupus nephritis only and normal controls (40% versus 69%, P = 0.012; 40% versus 81%, P < 0.001; respectively). (b) The ADAMTS-13 activity in patients with lupus nephritis plus TTP-HUS increased significantly from active phase to remission (40% versus 63%, P < 0.001). The levels of ADAMTS-13 activity were expressed in percentage. Fig. 3 . The prevalence of ADAMTS-13 autoantibodies was significantly higher in patients with lupus nephritis plus TTP-HUS (LN+TTP-HUS) than in patients with lupus nephritis only (LN only) and normal control (6/7, 86% versus 10/55, 18%, P < 0.001; 6/7, 86% versus 0, P < 0.001, respectively).
without TTP-HUS who also used prednisone plus cyclophosphamide in the same period in our hospital with comparable follow-up data from the whole 353 patients with lupus nephritis, which minus the seven patients with both TTP-HUS and lupus nephritis, were selected as disease control. Finally, 55 patients fulfilled the criteria. As shown in Tables 5 and 6 , the clinical and pathological data were compared between the two groups. In the lupus nephritis plus TTP-HUS group, there were significantly higher systolic and diastolic blood pressures, higher ratio of elevated serum LDH, the presence of schistocytes, thrombocytopaenia and acute renal failure, lower platelet count and haemoglobin level, higher serum creatinine, higher interstitial inflammation and higher CI, including glomerular sclerosis, tubular atrophy and interstitial fibrosis. The prevalence of TMA features was indeed significantly higher in patients with lupus nephritis plus TTP-HUS than in patients with lupus nephritis only.
We also detected serum ADAMTS-13 activity and the IgG ADAMTS-13 autoantibodies in the 55 patients during active phase and before initiation of immunosuppressive treatment. The activity was significantly lower in the 55 than in patients normal control (69%, ranging from 38% to 91% versus 81%, P = 0.03, Figure 2a) . However, for further comparison, the activity was significantly lower in patients with both lupus nephritis and TTP-HUS than in patients with lupus nephritis only (40% versus 69%, P = 0.012, Figure 2a ). The prevalence of ADAMTS-13 IgG antibodies was significantly higher in patients with both lupus nephritis and TTP-HUS than in patients with lupus nephritis only (6/7, 86% versus 10/55, 18%, P < 0.001, Figure 3) .
Regarding long-term outcome, the patients with lupus nephritis plus TTP-HUS had worse renal outcome. Two patients reached ESRD and one reached a doubling of serum creatinine in the TTP-HUS group, while four patients reached ESRD and two reached a doubling of serum creatinine in the lupus nephritis group without TTP-HUS. (3/7 versus 6/55, P = 0.024)
Discussion
SLE is a prototypic autoimmune disease, which comprises a range of multi-system disorders involving the deposition of aberrant immune complexes into tissues and organ systems. Renal involvement is common in SLE, and the total incidence of renal involvement among patients with SLE is ∼40% with variation depending on the geographic area [19, 20] . There are a number of different types of renal diseases in SLE, glomerulonephritis being the most common one. In addition to glomerulonephritis, physicians, including nephrologists and rheumatologists, should pay more attention to vascular diseases, such as TMA in patients with lupus nephritis, because its presence can adversely affect the prognosis of the renal disease [21] .
Our study showed that TTP-HUS-induced renal TMA could be found in 2.0% (7/353) of patients with renal biopsy-proven lupus nephritis, lower than previous reports [22] [23] [24] [25] . In the previous studies, authors found a higher prevalence of TMA with pure histological criteria. In the present series, TTP-HUS diagnosis was based on clinical and biological, but not on histological criteria. This is likely the explanation of a lower prevalence in our study. We focused on the cases of TTP-HUS without known causes in lupus nephritis in order to investigate the characteristics and pathogenesis of TTP-HUS in patients with lupus nephritis. As we know, this is a large series of lupus nephritis plus TTP-HUS from a single centre, although <100 isolated cases were reported in the literature [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] . The coexistence of SLE and TTP-HUS is not common, and the incidence of TTP-HUS occurring in the setting of SLE has been reported to be from 0.5% to 3% [41, 42] . An exact frequency cannot be calculated because patients with SLE and TTP-HUS share very similar clinical features such as fever, neurological disorders, renal injury, anaemia, thrombosis of small vessels and thrombocytopaenia. Therefore, it is difficult to differentiate between them clinically and the exact prevalence might be underestimated. In literature reviews [39, 43] , SLE preceded the diagnosis of TTP in most of the cases although our data supported higher concomitant ratio (71.4%).
Although no significant difference in the presence of fever, neurological disorder, anaemia and negative Coombs' test was noticed between lupus patients with and without TTP-HUS, the clinical evidence of MAHA such as elevated LDH and the presence of increased peripheral schistocytes may be helpful in identifying TTP-HUS clinically in patients with lupus nephritis. Renal histopathology could provide solid evidence of TMA.
The kidney is one of the most vulnerable organs both in TTP-HUS and SLE. Our current study suggested that patients with both lupus nephritis and TTP-HUS had much more severe renal injury compared with those with lupus nephritis only, although both settings had comparable diffuse proliferative lupus nephritis. The prevalence of acute renal injury and serum creatinine level were much higher in patients with both lupus nephritis and TTP-HUS than in those without TTP-HUS. These may be explained by renal histopathological TMA including severe swelling of endothelial cells and thrombi formation of small renal artery, arteriole and glomerular capillary, which result in narrowing or obliteration of the blood vessels and then reduction of glomerular filtration. In addition, we found that patients with both lupus nephritis and TTP-HUS had a significantly higher CI score, which may explain the worse long-term renal outcome of such patients.
Although the pathogenesis of TTP-HUS in SLE is not clear, considering the autoimmune nature of SLE, it is reasonable to speculate that autoimmunity may play a role in the pathogenesis of TTP-HUS in SLE [44] .
It has been reported that the deficiency or dysfunction of ADAMTS-13, the vWF-cp, may result in the survival of uncleaved or partially cleaved unusually large vWF multimers (UL-vWF) and may be the major cause of idiopathic TTP. Our results indicated that the serum ADAMTS-13 activity in patients with both lupus nephritis and TTP-HUS significantly decreased compared with healthy individuals. More importantly, all of the activity increased significantly after clinical remission, and the activity was significantly lower in patients with both lupus nephritis and TTP-HUS than in those with lupus nephritis only. In the literature, it was suggested that pathogenic autoantibodies to ADAMTS-13 might be the major cause of severe deficiency of idiopathic TTP [1, 6] . We demonstrated that the prevalence of ADAMTS-13 autoantibodies was significantly higher in patients with lupus nephritis and TTP-HUS than in patients with lupus nephritis only. Interestingly, five out of the six patients with positive ADAMTS-13 autoantibodies in the TTP-HUS group turned negative after clinical remission. It was speculated that the ADAMTS-13 autoantibodies might neutralize its enzyme activity and thus could lead to the survival of uncleaved vWF, which might subsequently lead to prothrombotic status [1, 6] . Our results highlighted the importance of ADAMTS-13 autoantibodies in the pathogenesis of TTP-HUS in lupus nephritis.
In our study, all seven patients achieved clinical remission of both lupus nephritis and TTP-HUS after plasma therapy and immunosuppressive therapy. Although there is no well-established guideline for the treatment of TTP-HUS in patients with lupus nephritis, most authors advised plasma exchange and immunosuppressive therapy [32, 45] . Vasoo S et al. [35] even suggested that cytotoxic agents may have an important role in the treatment of patients with active SLE and TTP-HUS refractory to plasmapheresis because they found that SLE activity and TTP-HUS activity ran a parallel course. Our observations further support an autoimmune contribution to the pathogenesis in both TTP-HUS and lupus nephritis.
The mortality of patients with both SLE with TTP-HUS is reported to be as high as 25-34% [36, 39] . It was suggested that the combination of the two diseases may have a worse prognosis than SLE or idiopathic TTP-HUS alone [40, 46] . Although no mortality occurred in our series, patients with both lupus nephritis and TTP-HUS indeed had a worse renal outcome compared with patients with diffuse proliferative lupus nephritis (IV-G) alone. This might be associated with the higher CI score in renal histopathology in patients with combined diseases.
In conclusion, the ADAMTS-13 autoantibody might play an important role in the pathogenesis of TTP-HUS in lupus nephritis. Although plasma therapy and immunosuppressive therapy could achieve clinical remission, their longterm outcome was poor.
